Frontiers of Medicine in China

, Volume 4, Issue 1, pp 54–58

Review of recent guidelines for the management of severe sepsis and septic shock

Review
  • 43 Downloads

Abstract

Severe sepsis and septic shock affect millions of patients and are major causes of mortality worldwide. Advancements in treatment and disease management led to a decline in in-hospital mortality from 27.8% (1979–1984) to 17.9% (1995 to 2000). In this article, we systemically review recent guidelines for the management of severe sepsis and septic shock published in 2008 by the International Surviving Sepsis Campaign Guidelines Committee. The 2008 Surviving Sepsis guidelines recommend protocolized resuscitation with goals to maintain central venous pressure ⩾ 8–12 mmHg, mean arterial pressure ⩾ 65 mmHg, urine output ⩾ 0.5 mL·kg−1·h−1 and central venous oxygen saturation ⩾ 70% (or mixed venous ⩾ 65%). Further fluid administration, transfusion of packed red blood cells to achieve a hematocrit of ⩾ 30% and/or infusion of dobutamine max 20 μg·kg−1·min−1 are advised if venous O2 saturations remain below 70%. In patients with decreased ventricular compliance or mechanical ventilation, a target central venous pressure of 12–15 mmHg is recommended. Intravenous antibiotic administration within the first hour of recognizing severe sepsis and septic shock is essential, while use of corticosteroids in sepsis is controversial. The mechanisms by which activated protein C improves clinical outcomes in sepsis are unknown. Therapy with activated protein C is approved for patients with severe sepsis and an increased risk of death [Acute Physiology and Chronic Health Evaluation II (APACHE II) > 25]. Bicarbonate therapy is discouraged. Intravenous insulin should be used to control hyperglycemia in patients with severe sepsis following stabilization in the intensive care unit.

Keywords

sepsis septic shock hemodynamics guidelines 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med, 1992, 20(6): 864–874Google Scholar
  2. 2.
    Levy M M, Fink M P, Marshall J C, Abraham E, Angus D, Cook D, Cohen J, Opal S M, Vincent J L, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med, 2003, 31(4): 1250–1256CrossRefPubMedGoogle Scholar
  3. 3.
    Balk R A. Severe sepsis and septic shock. Definitions, epidemiology, and clinical manifestations. Crit Care Clin, 2000, 16(2): 179–192CrossRefPubMedGoogle Scholar
  4. 4.
    Angus D C, Wax R S. Epidemiology of sepsis: an update. Crit Care Med, 2001, 29(7 Suppl): S109–116CrossRefPubMedGoogle Scholar
  5. 5.
    Martin G S, Mannino D M, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med, 2003, 348(16): 1546–1554CrossRefPubMedGoogle Scholar
  6. 6.
    Dellinger R P, Levy M M, Carlet JM, Bion J, Parker M M, Jaeschke R, Reinhart K, Angus D C, Brun-Buisson C, Beale R, Calandra T, Dhainaut J F, Gerlach H, Harvey M, Marini J J, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson B T, Townsend S, Vender J S, Zimmerman J L, Vincent J L; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: International guidelines for the management of severe sepsis and septic shock. Crit Care Med, 2008, 36(1): 296–327CrossRefPubMedGoogle Scholar
  7. 7.
    Kieft H, Hoepelman A I, Zhou W, Rozenberg-Arska M, Struyvenberg A, Verhoef J. The sepsis syndrome in a Dutch university hospital: clinical observations. Arch Intern Med, 1993, 153(19): 2241–2247CrossRefPubMedGoogle Scholar
  8. 8.
    Reinhart K, Wiegand-Löhnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody fragment, MAK195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med, 1996, 24(5): 733–742CrossRefPubMedGoogle Scholar
  9. 9.
    Pittet D, Thiévent B, Wenzel R P, Li N, Auckenthaler R, Suter P M. Bedside prediction of mortality from bacteremic sepsis: dynamic analysis of ICU patients. Am J Respir Crit Care Med, 1996, 153(2): 684–693PubMedGoogle Scholar
  10. 10.
    Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Eng J Med, 2001, 345(19): 1368–1377CrossRefGoogle Scholar
  11. 11.
    Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med, 2004, 350(22): 2247–2256CrossRefPubMedGoogle Scholar
  12. 12.
    Holmes C L, Patel B M, Russell J A, Walley K R. Physiology of vasopressin relevant to management of septic shock. Chest, 2001, 120(3): 989–1002CrossRefPubMedGoogle Scholar
  13. 13.
    Russell J A, Walley K R, Singer J, Gordon A C, Hébert P C, Cooper D J, Holmes C L, Mehta S, Granton J T, Storms M M, Cook D J, Presneill J J, Ayers D; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med, 2008, 358(9): 877–887CrossRefPubMedGoogle Scholar
  14. 14.
    Holmes C L, Walley K R. Bad medicine: low-dose dopamine in the ICU. Chest, 2003, 123(4): 1266–1275CrossRefPubMedGoogle Scholar
  15. 15.
    Hamrahian A H, Oseni T S, Arafah B M. Measurements of free cortisol in critically ill patients. N Engl J Med, 2004, 350(16): 1629–1638CrossRefPubMedGoogle Scholar
  16. 16.
    Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia, 1999, 54(9): 861–867CrossRefPubMedGoogle Scholar
  17. 17.
    Sprung C L, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss Y G, Benbenishty J, Kalenka A, Forst H, Laterre P F, Reinhart K, Cuthbertson B H, Payen D, Briegel J; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med, 2008, 358(2): 111–124CrossRefPubMedGoogle Scholar
  18. 18.
    Annane D, Bellissant E, Bollaert P E, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ, 2004, 329(7464): 480CrossRefPubMedGoogle Scholar
  19. 19.
    Annane D, Sébille V, Charpentier C, Bollaert P E, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaud P, Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA, 2002, 288(7): 862–871CrossRefPubMedGoogle Scholar
  20. 20.
    Bernard G R, Vincent J L, Laterre P F, LaRosa S P, Dhainaut J F, Lopez-Rodriguez A, Steingrub J S, Garber G E, Helterbrand J D, Ely E W, Fisher C J Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant activated protein C for severe sepsis. N Engl J Med, 2001, 344(10): 699–709CrossRefPubMedGoogle Scholar
  21. 21.
    Abraham E, Laterre P F, Garg R, Levy H, Talwar D, Trzaskoma B L, François B, Guy J S, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback B G, Macias W L; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med, 2005, 353(13): 1332–1341CrossRefPubMedGoogle Scholar
  22. 22.
    Hébert P C, Wells G, Blajchman M A, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion in critical care. N Engl J Med, 1999, 340(6): 409–417CrossRefPubMedGoogle Scholar
  23. 23.
    Corwin H L, Gettinger A, Rodriguez R M, Pearl R G, Gubler K D, Enny C, Colton T, Corwin M J. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized doubleblind, placebo-controlled trial. Crit Care Med, 1999, 27(11): 2346–2350CrossRefPubMedGoogle Scholar
  24. 24.
    The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med, 2000, 342(18): 1301–1308CrossRefGoogle Scholar
  25. 25.
    National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann H P, Wheeler A P, Bernard G R, Thompson B T, Hayden D, deBoisblanc B, Connors A F Jr, Hite R D, Harabin A L. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med, 2006, 354(24): 2564–2575CrossRefPubMedGoogle Scholar
  26. 26.
    Truog R D, Campbell M L, Curtis J R, Haas C E, Luce J M, Rubenfeld G D, Rushton C H, Kaufman D C; American Academy of Critical Care Medicine. Recommendations for end-of-life care in the intensive care unit: a consensus statement by the American Academy of Critical Care Medicine. Crit Care Med, 2008, 36(3): 953–963CrossRefPubMedGoogle Scholar
  27. 27.
    Antonelli M, Mercurio G. The 2008 international guidelines for management of severe sepsis and septic shock: merits and weaknesses. Minerva Anestesiol, 2009, 75(1,2): 27–29PubMedGoogle Scholar

Copyright information

© Higher Education Press and Springer Berlin Heidelberg 2010

Authors and Affiliations

  • Jin-Nong Zhang
    • 1
  • Bo Peng
    • 1
  • Jamile Woods
    • 2
  • Wei Peng
    • 2
  1. 1.Pulmonary Division of Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of Pulmonary and Sleep MedicineSalt Lake Regional Medical Center, Iasis HealthcareSalt Lake CityUSA

Personalised recommendations